HIF1A and bone neoplasm: Furthermore, we performed multiplex IHC staining in those bone tumors and found that pro-tumoral TAMs (F4/80+CD206+) were significantly reduced in ASH1L-expressing tumors upon HIF-1α inhibitor treatment (Fig. 7i and Supplementary Fig. 9h).